FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
On March 1, 2024, the FDAapproved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 1, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Early Mesothelioma Vaccine Testing Shows Promise
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Sean Marchese Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Early Mesothelioma Vaccine Testing Shows Survival Gains
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Sean Marchese Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Phase I Trial Improves Mesothelioma Survival More Than 200%
Sellas Life Sciences reports its Phase I clinical trial showed improvement of overall survival in patients with pleural mesothelioma. The study focused on a new potential therapy called GPS (galinpepimut-S), an immunotherapy vaccine.
The trial included 10 patients with relapsed or refractory mesothelioma, nine of whom received at least three doses of GPS. Researchers gave the third dose of GPS alongside the checkpoint inhibitor Opdivo (nivolumab).
President of Sellas, Angelos Stergiou, stated in a press release, “As we had hypothesized in the past, this increase in survival appears to be consistent with long-...
Source: Asbestos and Mesothelioma News - January 31, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Clinical Trials/Research/Emerging Treatments Immunotherapy Mesothelioma Source Type: news
Polaris Submits Application for New Mesothelioma Treatment
Multinational biopharmaceutical company Polaris Group announced their application for a rolling submission of a new mesothelioma treatment this month. The Biologic License Application for the experimental drug ADI-PEG 20 is the first step in U.S. Food and Drug Administration approval.
The application outlines the use of ADI-PEG 20 for non-epithelioid mesothelioma alongside treatment with pemetrexed and platinum chemotherapy. Non-epithelioid subtypes include sarcomatoid and biphasic cell types, historically the most resistant to treatment.
Polaris stated in a press release, “Polaris Group’s development...
Source: Asbestos and Mesothelioma News - December 14, 2023 Category: Environmental Health Authors: Amy Edel Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
Pembrolizumab + Standard Chemotherapy Beneficial in Mesothelioma
WEDNESDAY, Nov. 15, 2023 -- The addition of pembrolizumab to standard platinum-pemetrexed chemotherapy results in significant improvement in overall survival among patients with advanced pleural mesothelioma, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 15, 2023 Category: Pharmaceuticals Source Type: news
Trial Shows Keytruda With Chemotherapy Superior to Chemo Alone
Results of a new phase 3 clinical trial published in the Journal of Clinical Oncology indicate that a chemoimmunotherapy regimen combining chemotherapy with immunotherapy drugs improves patient survival more than chemotherapy alone for pleural mesothelioma.
Study researchers used pembrolizumab (Keytruda) alongside platinum and pemetrexed chemotherapy. Christina S. Baik, MD, MPH, reviewed the phase 3 trial results during the American Society of Clinical Oncology’s 2023 Best of ASCO Seattle annual meeting.
The overall response rate for patients receiving Keytruda with chemotherapy was 63% compared to 40% for th...
Source: Asbestos and Mesothelioma News - September 13, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Chemotherapy/Chemo drugs Immunotherapy Mesothelioma Treatment Source Type: news
Study Questions Use of Aggressive Surgery in Early Mesothelioma
(MedPage Today) -- SINGAPORE -- Extended pleurectomy/decortication combined with platinum and pemetrexed chemotherapy was associated with worse outcomes in patients with resectable mesothelioma compared with chemotherapy alone, according to a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 12, 2023 Category: Hematology Source Type: news
MARS Trial: Decortication and Chemotherapy Associated with Worse Outcomes for Patients with Resectable Mesothelioma
Extended pleurectomy decortication combined with chemotherapy is associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life compared to platinum and pemetrexed chemotherapy alone, according to research presented today at the... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 11, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
Chemoimmunotherapy Safe, Effective for Untreated Lung Cancer Brain Metastases
(MedPage Today) -- Chemoimmunotherapy for untreated lung cancer brain metastases delayed progression and use of whole-brain radiation, a prospective phase II study showed.
Atezolizumab (Tecentriq) plus carboplatin and pemetrexed led to a 12-week... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 24, 2023 Category: Hematology Source Type: news
Phase 3 Keytruda, Chemotherapy Mesothelioma Trial Shows Promising Results
Pharmaceutical company Merck says use of its immunotherapy drug Keytruda in conjunction with chemotherapy increases the survival rate for people with advanced pleural mesothelioma, according to the latest results of a phase 3 clinical trial.
The results were announced in June at the annual meeting of the American Society of Clinical Oncology. They showed Merck’s use of the anti-PD-1 treatment combined with chemotherapy reduced the patient’s risk of death by 21%.
Clinical trial results of the multimodal treatment using immunotherapy and chemo also showed a median overall survival of 17.3 months in comparison...
Source: Asbestos and Mesothelioma News - June 26, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
New RYBREVANT ® (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
COPENHAGEN, DENMARK, March 29, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new long-term data from the CHRYSALIS study evaluating RYBREVANT® (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy.1 Data from the study showed long-term response and safety in this population and were presented in an oral presentation at the 2023 European Lung Cancer Congress (ELCC) (Abstract #779).1In the analysis of the CHRYSALIS study, inve...
Source: Johnson and Johnson - March 29, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Study: Cancer Enzyme Slows Growth of Pleural Mesothelioma
Patients with pleural mesothelioma may extend their survival by an estimated 30% when the latest anti-cancer enzyme is added to standard chemotherapy, according to a recently completed study.
AGI-PEG 20 showed unprecedented effectiveness when treating patients with sarcomatoid mesothelioma and biphasic mesothelioma – the most treatment-resistant subtypes – in an international, multicenter, phase II/III clinical trial known as ATOMIC Meso.
The enzyme works by limiting an amino acid known as arginine that often fuels tumor cells. It depletes its effectiveness in promoting tumor growth, leading to longer survival. ...
Source: Asbestos and Mesothelioma News - October 13, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news
Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT ® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations
July 26, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1b/2 CHRYSALIS-2 study (NCT04077463) cohort evaluating the safety and tolerability of the combination of RYBREVANT® (amivantamab-vmjw) with the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) lazertinib and platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer (NSCLC) and EGFR mutations.[1] These findings and additional updates, including data on RYBREVANT® in combination with laze...
Source: Johnson and Johnson - July 26, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
